These complications or untoward effects often occurred simultaneously. Discussion AIDS-related lymphomas (ARLs) occur mainly among more advanced AIDS patients. DLBCL required CHOP 6 occasions. Three patients with DLBCL required CHOP 1 or 2 2 times. Four patients gave up treatment. Numerous infections and side effects occurred, including bone marrow suppression, gastrointestinal bleeding, and renal dysfunction during Edotecarin chemotherapy. Six patients required HAART, and 4 did not. Six patients died, whereas 3 patients got improved; and 1 patient was discharged. Conclusions AIDS patients with malignant lymphoma experienced various clinical manifestations, were immunocompromised, and experienced multiple metastases when they were admitted; they were already Edotecarin in the interim or late stage of lymphoma. Chemotherapy was not effective, and additional complications occurred. HAART failed to improve patient prognosis, and the overall prognosis was poor. strong class=”kwd-title” KEY WORDS: acquired immunodeficiency syndrome (AIDS), malignant lymphoma, chemotherapy, HAART, prognosis Introduction Acquired Immunodeficiency Syndrome (AIDS) patients often develop opportunistic infections and malignant tumors because of their low immune function. Studies found that 3.3% of newly diagnosed AIDS patients experienced non-Hodgkins lymphoma (NHL) . Most of these patients were in the middle or late stages of the disease when they saw a doctor. Thus, monotherapy is usually often ineffective . The most effective method is combined treatment. This study summarizes and analyzes the clinical data and treatment of 10 AIDS patients with malignant lymphoma. Patients and Methods Patients The First Department of Infectious Diseases of the Beijing Ditan Hospital admitted and treated 10 AIDS patients with malignant lymphoma between January 2008 and December 2010. The diagnostic criteria used were from your diagnostic standard of adult HIV/AIDS formulated by the U.S. Centers for Disease Control and Prevention (CDC) in 1993. The diagnostic criteria for malignant lymphoma used were from your Tumor Section of the Chinese Medical Association Clinical Practice Guidelines. The antibody test for AIDS used confirmatory Western blot conducted in the lab of the local Center for Disease Control and Prevention to confirm the presence of positive HIV-1 antibodies. Immunoassay The CD4+ cell count was decided in the research laboratory of the Beijing Ditan Hospital. FACS Calibur Edotecarin circulation cytometry was used in the test; the instrument and reagent were supplied by the U.S. BD organization. Reagents DNAJC15 used in the test were TriTEST three-color reagent, MultiTEST four-color reagent, and FACS hemolysin. The quality was controlled by absolute counting. To test for malignant lymphoma, abnormal tissues from different locations, including lymph node, gastric mucosa, colonic mucosa, galactophore, and brain were analyzed through histopathology, cytology, and immunohistochemical detection. Clinical staging was based on the Ann Arbor Edotecarin clinical stages program. Statistical analysis Students em t /em -test or variance analysis was utilized for data analysis. SPPS 10.0 software was used. Results Epidemiology and clinical manifestation One case was infected through blood, 3 cases were infected through sexual intercourse, and 3 cases had unknown routes of transmission. Five cases experienced enlargement of superficial lymph nodes, 2 cases were accompanied by fever, 2 cases experienced intermittent fever and 3 cases experienced abdominal pain and distension accompanied by fever. Clinical data and treatment end result of patients Please observe Table 1. Table 1 Clinical data and treatment end result of patients. thead th valign=”middle” align=”left” scope=”col” rowspan=”1″ colspan=”1″ No. /th th valign=”middle” align=”left” scope=”col” rowspan=”1″ colspan=”1″ Gender /th th valign=”middle” align=”left” scope=”col” rowspan=”1″ colspan=”1″ Age, br / years /th th valign=”middle” align=”left” scope=”col” rowspan=”1″ colspan=”1″ Course of br / disease /th th valign=”middle” align=”left” scope=”col” rowspan=”1″ colspan=”1″ Main site /th th valign=”middle” align=”left” scope=”col” rowspan=”1″ colspan=”1″ HAART /th th valign=”middle” align=”left” scope=”col” rowspan=”1″ colspan=”1″ Chemotherapy /th th valign=”middle” align=”left” scope=”col” rowspan=”1″ colspan=”1″ Survival time /th th valign=”middle” align=”left” Edotecarin scope=”col” rowspan=”1″ colspan=”1″ End result /th /thead 1Male463 monthsAxillary nodesAZT/3TC/NVPVP/CODOXM/IVAC 1 yearPartial remission2Female401 monthStomachd4T/3TC/NVPR-CHOP/R-MINE/MINE1.5 yearsComplete emission3Male561 yearAdrenal br / glandsd4T/3TC/NVPCHOP 1 yearDied of renal failure4Male572 monthsCervical lymph br / noded4T/3TC/EFVR-CHOPNo follow-upImproved5Female3020 daysBreastNonAbandoned treatment1 monthDied of lymphoma6Male301 monthCervical lymph br / noded4T/3TC/EFVRecommended br / CHOP+/-ENo follow-upHome treatment7Male281 monthCervical lymph br / nodeNonAbandoned treatment2 monthsDied of lymphoma8Male311 yearEncephalicd4T/3TC/NVPDexamethasone2 monthsDied of lymphoma9Male482 monthsAxillary nodesNonCHOP2 monthsDied of toxic shock10Male481 yearColonNonCHOP6 monthsDied of severe anemia Open in a separate window d4T: stavudine; AZT: zidovudine;.